Macrophage mod 
Welcome,         Profile    Billing    Logout  
 12 Companies  10 Products   10 Products   29 Diseases   8 Trials   274 News 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tetrachlorodecaoxide / Generic mfg.
2013-003096-35: Investigation of the effects of novel medication and its constituents in patients with allergic rhinitis that is not responsive to conventional medication

Ongoing
1/2
184
Europe
WF10, NRI-1025, NRI-1026, NRI-1025-01, NRI-1026-01,
Nuvo Research GmbH, NUVO Research GmbH
refractory allergic rhinitis
 
 
Imprime PGG (odetiglucan) / HiberCell
MK-3475-C99, NCT05159778: Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)

Completed
2
26
US
Imprime PGG, Imprime, BTH-1677, Pembrolizumab, Keytruda
HiberCell, Inc., Merck Sharp & Dohme LLC
Malignant Neoplasm of Breast
03/23
04/23
NCT03003468: Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017

Completed
1/2
35
US
Imprime PGG, MK-3475, pembrolizumab, Keytruda
Lawrence Feldman, MD, Merck Sharp & Dohme LLC, HiberCell, Inc.
Non-Small Cell Lung Cancer
11/21
11/22
NCT05484011: A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Terminated
1
5
US
odetiglucan, Imprime, BTH-1677, Imprime PGG, CDX-1140
HiberCell, Inc., Celldex Therapeutics
Metastatic Pancreatic Adenocarcinoma
03/24
03/24
MP1032 / MetrioPharm
2017-003484-36: A study to evaluate the efficacy of the new drug MP1032 in patients with moderate-to-severe psoriasis

Not yet recruiting
2
150
Europe
MP1032 hard gelatin capsules 50 mg, MP1032, Capsule, hard
MetrioPharm AG, MetrioPharm AG
chronic Psoriasis Plaque moderate-to-severe chronische Schuppenflechte mit einer moderaten-bis-schweren Ausprägung, chronic Psoriasis Plaque moderate-to-severe chronische Schuppenflechte mit einer moderaten-bis-schweren Ausprägung, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
fosfomycin/metronidazole/granulocyte macrophage colony stimulating factor (RNX-041) / Reponex Pharma
2020-000609-10: A combination of immunesystem stimulating- and antibiotic treatment for inflammation of the pouch in ulcerative colitis patients

Not yet recruiting
1/2
26
Europe
Repomol, Metronidazole, Infectofos, Solution for infusion, Powder for infusion, Metronidazole, Fosfomycin
Center for Surgical Science, Reponex A/S
A combination of GM-CSF and metronidazole/fosfomycin treatment for pouchitis in Ulcerative Colitis patients after ileal-pouch-anal anastomosis surgery given as an enema or spray in the pouch., We want to test a new combination with two antibiotics and a drug to stimulate the immune system given locally in the pouch in patients that have inflammation after surgery for colitis., Diseases [C] - Digestive System Diseases [C06]
 
 
NCT04979832: GM-CSF, Fosfomycin and Metronidazole for Pouchitis in Ulcerative Colitis Patients After Restorative IPAA Surgery

Recruiting
1/2
18
Europe
GM-CSF, fosfomycin and metronidazole, GM-CSF, Fosfomycin, Metronidazole
Zealand University Hospital
Pouchitis
12/23
12/23
CT-1119 / CARISMA Therap
No trials found
In-Vivo mRNA CAR-M targeting GPC-3 / Moderna
No trials found
iPSC derived M2 macrophage cell therapy / Shoreline Biosci
No trials found
ArsciCor (arsenic trioxide oral) / BioSenic
No trials found
MAD-paclitaxel therapy / Navidea
No trials found
MAD-bisphosphonate therapy / Navidea
No trials found
AVS200 / Avstera
No trials found
COYA 302 / Coya Therap, Dr. Reddy’s
No trials found
RCT001 / Roca Therap
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tetrachlorodecaoxide / Generic mfg.
2013-003096-35: Investigation of the effects of novel medication and its constituents in patients with allergic rhinitis that is not responsive to conventional medication

Ongoing
1/2
184
Europe
WF10, NRI-1025, NRI-1026, NRI-1025-01, NRI-1026-01,
Nuvo Research GmbH, NUVO Research GmbH
refractory allergic rhinitis
 
 
Imprime PGG (odetiglucan) / HiberCell
MK-3475-C99, NCT05159778: Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)

Completed
2
26
US
Imprime PGG, Imprime, BTH-1677, Pembrolizumab, Keytruda
HiberCell, Inc., Merck Sharp & Dohme LLC
Malignant Neoplasm of Breast
03/23
04/23
NCT03003468: Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017

Completed
1/2
35
US
Imprime PGG, MK-3475, pembrolizumab, Keytruda
Lawrence Feldman, MD, Merck Sharp & Dohme LLC, HiberCell, Inc.
Non-Small Cell Lung Cancer
11/21
11/22
NCT05484011: A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Terminated
1
5
US
odetiglucan, Imprime, BTH-1677, Imprime PGG, CDX-1140
HiberCell, Inc., Celldex Therapeutics
Metastatic Pancreatic Adenocarcinoma
03/24
03/24
MP1032 / MetrioPharm
2017-003484-36: A study to evaluate the efficacy of the new drug MP1032 in patients with moderate-to-severe psoriasis

Not yet recruiting
2
150
Europe
MP1032 hard gelatin capsules 50 mg, MP1032, Capsule, hard
MetrioPharm AG, MetrioPharm AG
chronic Psoriasis Plaque moderate-to-severe chronische Schuppenflechte mit einer moderaten-bis-schweren Ausprägung, chronic Psoriasis Plaque moderate-to-severe chronische Schuppenflechte mit einer moderaten-bis-schweren Ausprägung, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
fosfomycin/metronidazole/granulocyte macrophage colony stimulating factor (RNX-041) / Reponex Pharma
2020-000609-10: A combination of immunesystem stimulating- and antibiotic treatment for inflammation of the pouch in ulcerative colitis patients

Not yet recruiting
1/2
26
Europe
Repomol, Metronidazole, Infectofos, Solution for infusion, Powder for infusion, Metronidazole, Fosfomycin
Center for Surgical Science, Reponex A/S
A combination of GM-CSF and metronidazole/fosfomycin treatment for pouchitis in Ulcerative Colitis patients after ileal-pouch-anal anastomosis surgery given as an enema or spray in the pouch., We want to test a new combination with two antibiotics and a drug to stimulate the immune system given locally in the pouch in patients that have inflammation after surgery for colitis., Diseases [C] - Digestive System Diseases [C06]
 
 
NCT04979832: GM-CSF, Fosfomycin and Metronidazole for Pouchitis in Ulcerative Colitis Patients After Restorative IPAA Surgery

Recruiting
1/2
18
Europe
GM-CSF, fosfomycin and metronidazole, GM-CSF, Fosfomycin, Metronidazole
Zealand University Hospital
Pouchitis
12/23
12/23
CT-1119 / CARISMA Therap
No trials found
In-Vivo mRNA CAR-M targeting GPC-3 / Moderna
No trials found
iPSC derived M2 macrophage cell therapy / Shoreline Biosci
No trials found
ArsciCor (arsenic trioxide oral) / BioSenic
No trials found
MAD-paclitaxel therapy / Navidea
No trials found
MAD-bisphosphonate therapy / Navidea
No trials found
AVS200 / Avstera
No trials found
COYA 302 / Coya Therap, Dr. Reddy’s
No trials found
RCT001 / Roca Therap
No trials found

Download Options